NCT07450820 OPTIMISE-CKD Study_Dapagliflozin Effectiveness in CKD
| NCT ID | NCT07450820 |
| Status | Recruiting |
| Phase | — |
| Sponsor | AstraZeneca |
| Condition | Chronic Kidney Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 14,308 participants |
| Start Date | 2026-02-18 |
| Primary Completion | 2027-02-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 14,308 participants in total. It began in 2026-02-18 with a primary completion date of 2027-02-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a retrospective, observational study, using secondary data captured in electronic health records (EHRs). The study is a part of the OPTIMISE-CKD program to assess the current CKD treatment landscape, Dapagliflozin utilisation and characterization of incident CKD patient and the burden of disease within an observation period of 39 months (August 2020-November 2024) in two cohorts (preand post-reimbursement of Dapagliflozin for CKD)
Eligibility Criteria
Inclusion Criteria: * Meets CKD definition criteria: having at least two eGFR measures ≤60 ml/min/1.73m2 measured ≥90 to 730 days apart and/or UACR ≥ 30 mg/g, and/or at least one measurement indicative of proteinuria (or with proteinuria ERA-ICD code) or CKD code. * Age ≥18 years. * 12 months continuous enrolment in the data base prior to index * 12 months continuous enrolment in the data base after index date. Exclusion Criteria: * T1DM on or before index date. * Diagnosis of gestational diabetes mellitus on or before index date
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07450820 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 130 Years, studying Chronic Kidney Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07450820 currently recruiting?
Yes, NCT07450820 is actively recruiting participants. Contact the research team at information.center@astrazeneca.com for enrollment information.
Where is the NCT07450820 trial being conducted?
This trial is being conducted at Madrid, Spain.
Who is sponsoring the NCT07450820 clinical trial?
NCT07450820 is sponsored by AstraZeneca. The trial plans to enroll 14,308 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.